Immunovia announces positive outcome and strong accuracy in the clinical validation of its next-generation test for pancreatic cancer

LUND, Sweden, Dec. 9, 2024 /PRNewswire/ — Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, today announces the successful completion of the CLARITI study, (Clinical Validation of Next-Generation Test for Early-Stage Pancreatic Cancer) to detect early-stage pancreatic…